4 Ebola Researching Biotech Companies For Your Portfolio

With the death toll from West Africa’s Ebola outbreak reaching close to 1,000, serious interested is being taken into researching compounds that could both prevent outbreak and help those infected.

Until recently, Ebola was a pretty rare disease, Dr. Jim Wilson told Benzinga, and the healthcare sector is very market-driven.

Wilson is the executive director of Ascel Bio and director of the Ascel Bio National Infectious Disease Forecast Center. He said that in the past, more attention has been given to research on illnesses like Malaria and Cholera.

But the current Ebola outbreak is a category six on the Infectious Disease Impact Scale, Wilson said, which means it could have maximum social disruption.

“In modern society, Ebola is the archetype of an infectious disaster,” he said.

In response, many companies are reviving or starting brand new research campaigns for ways to combat the Ebola virus.

"This could be a big win for the company that has a drug for it [Ebola]," MLV & Co. analyst Dr. George Zavoico told Benzinga. 

Here are a few to watch in the upcoming weeks:

BioCryst Pharmaceuticals Inc. BCRX

This Durham, North Carolina-based biotech company has a market cap of close to $1 billion. There are four compounds in BioCryst’s pipeline, including Peramivir, an influenza treatment legal in Japan and Korea, and BCX4430, a “broad-spectrum” treatment for a number of viruses.

While BioCryst is not currently responding to media requests, and will not say whether Ebola is one of the viruses that BCX4430 could treat, Forbes and analysts say that it might work as an Ebola treatment.

“They have said that they are working on the compound for a bunch of different viruses, and Ebola could be one of them,” MLV & Co. analyst Vernon Bernardino told Benzinga.

BioCryst stock has slowly risen above the $10-level since the beginning of June, and is currently sitting at $12-13.

NanoViricides Inc. NNVC

NanoViricides announced earlier this week that it will restart its anti-ebola virus drug development program. This nano-biopharmaceutical company is based out of West Haven, Connecticut, and has a market cap of about a quarter billion dollars.

NanoViricides originally began researching an anti-Ebola drug about four or five years ago, CEO Eugene Seymour told Benzinga. He said the drug will end up being much better than if it had been developed back then because of the advancements in technology and research.

The company’s stock went from $3 a share to almost $5, but is now hovering right around the $4 mark.

Tekmira Pharmaceuticals Corp TKMR

Tekmira is listed both in the United States and on the Toronto Stock Exchange. This British Columbia-based biopharmaceutical company has a market cap of a little more than $300 million.

Its pipeline includes TKM-Ebola, an anti-Ebola viral RNAi theraputic. In March of this year, according to Tekmira’s website, the U.S. Food and Drug Administration granted the company a Fast Track designation to expedite the review of drugs so they can be put to use faster.

Tekmira’s stock jumped to $30 a share in March, but has since dropped down to the $14-level. It experienced a pop to almost $16 earlier this week, but has fallen below $14 since.

NewLink Genetics Corporation NLNK

While most companies are working on treatments, NewLink just received a $1 million contract from the U.S. Defense Threat Reduction Agency to conduct studies for an Ebola vaccine. This Ames, Iowa-based company has a market cap of more than $600 million.

Through its wholly owned subsidiary, BioProtection Systems Corporation, NewLink is able to conduct studies that will bring an Ebola vaccine closer to human clinical trials.

Although NewLink’s stocks has been falling from $50 to the $20-level from earlier this year, it jumped from $20 per share to almost $24 since the news of its government contract came out this week.

Posted In: biotech sectorEbolapharmaceuticalsBiotechHealth CareTechTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.